-+ 0.00%
-+ 0.00%
-+ 0.00%
Zydus Therapeutics Presents Phase 2b Data at AASLD 2026 Showing Greater Resolution of Steatohepatitis Without Worsening of Fibrosis With Investigational Saroglitazar Compared to Placebo in Adults With MASH and Fibrosis
Share
Listen to the news

AHMEDABAD, India and PENNINGTON, N.J., Nov. 6, 2026 /PRNewswire/ -- Zydus Therapeutics Inc. ("Zydus Therapeutics"), a wholly owned subsidiary of Zydus Lifesciences Limited, a global innovation-led healthcare company, today announced results from a Phase 2b randomized, double-blind, placebo-controlled clinical trial of saroglitazar in adults with biopsy-confirmed MASH and stage F2–F3 fibrosis. The results will be presented as a late-breaking oral presentation at The Liver Meeting® 2026, the annual meeting of the American Association for the Study of Liver Diseases (AASLD).

Read more at prnewswire.com

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending